Documents

Q2 revenue up 10% year-over-year; 2026 guidance raised; IFC revenue to grow 40–50%.

All proposals passed, including director elections and plan amendments, with no shareholder questions.

Q1 revenue up 24% year-over-year, with raised guidance and strong global demand for core products.

Record revenue growth and global expansion driven by INTERCEPT blood safety technologies.

Record 2025 growth and global expansion highlight strong momentum in blood safety innovation.

Double-digit growth driven by U.S. and global expansion, new products, and strong partnerships.

Record revenue and strong growth in 2025 set the stage for continued expansion in 2026.

Record Q3 revenue and raised guidance highlight strong growth and expanding profitability.

Strong growth, new product launches, and global expansion drive future opportunities.

Record Q2 revenue and raised 2025 outlook driven by strong IFC and platelet growth.

Market-leading blood safety technology drives growth, innovation, and global expansion.

Q1 2025 saw 13% revenue growth, improved margins, and continued global expansion.

15% revenue growth and positive adjusted EBITDA in 2024 set the stage for further expansion in 2025.

Strong U.S. market share, global expansion, and new products drive robust multi-year growth.

15% revenue growth, positive EBITDA, and global expansion set the stage for 2025 gains.